Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells.
The test aims to enhance ultra-sensitive detection of MRD through a non-invasive approach. It is designed to provide sensitivity comparable to next-generation sequencing methods, but at a significantly lower cost, supporting improved patient care.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Quest test offers next-generation flow cytometry capabilities and uses only non-invasive blood samples. It does not require baseline aspirate samples as next-generation sequencing (NGS) does.
It also features five-day specimen stability, compared to three or fewer days with conventional flow cytometry, which could improve access when specimen transport times are longer. This feature aims to make the test feasible even when baseline samples are unavailable.
Quest expects the new blood test will also support response monitoring in clinical trials. The FDA issued draft guidance in January 2026 endorsing MRD as a primary endpoint in multiple myeloma drug trials for accelerated approval.
Quest senior vice-president and chief medical officer Yuri Fesko said: “Our flow cytometry MRD for myeloma test harnesses cutting-edge science and technology to deliver ultra-sensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This new test merges this elite performance with improved access, given Quest’s approximately 7,000 phlebotomy sites across the US, helping to illuminate a path to better health for more patients.”
Quest provides oncology testing services, including the Haystack MRD test for solid tumours. This offering extends the company’s portfolio of haematopathology and molecular oncology testing services.
In September 2025, Quest introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications.
